Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
June 05, 2023
Recent CGD events have shown several bright spots for the evidence-informed policy agenda, demonstrating leadership commitment to evidence generation and use. The new World Bank president, Ajay Banga, called for the institution to deepen its role as a knowledge bank in a recent speech at CGD. Newly ...
Blog Post
May 01, 2023
Under a new Memorandum of Understanding, USAID, the William and Flora Hewlett Foundation, and CGD plan to partner in exploring locally led evaluation and evidence generation approaches, with an initial focus in sub-Saharan Africa. An opportunity to advance evidence-informed policymaking and locally ...
Blog Post
April 24, 2023
As World Immunization Week kicks off today, childhood vaccination remains among the most cost-effective uses of health spending. Significant progress has been made to expand global vaccine coverage. Yet, rates remain inequitable and highly variable—within countries but also across those in the same ...
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Blog Post
January 25, 2023
Last month, the Center for Global Development (CGD), the White House Office of Science and Technology Policy, and the Office of Management and Budget co-hosted an Evidence Forum as part of the White House Year of Evidence for Action, featuring USAID Administer Samantha Power. The event celebrated pr...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.